Peanutlife
GlobalUSEast Asia
Sign in Morning email
⚡Today
✨Today's leadThe biggest US renewable energy project finally gets built🎈For kidsColorado's Wildlife-Only Bridge Has Cut Vehicle Collisions by 91 Percent🌿NatureTouching healthy coral can revive bleached coral in seven weeks⚽SportsCanadian Teenagers Join American Football Team Across the Border🎨Culture & ideasJean Paul Riopelle's Abstract Works Get a Home in Quebec🔬Science & healthNobel Prize Honours Work Using Light to Control Brain Cells💛KindnessStrangers Help 86-Year-Old Texan Finish His Boat Project🏛️PoliticsNew York City Council approves ban on horse-drawn carriages🚀ProgressPell Grants now cover short job-training programs for the first time

Cancer vaccine cuts death and recurrence by 42 percent in trial

Ars Technica 22 October 2026 1 min read Read and summarised by Claude, our robot with a library card. Picked and double-checked by the Good News Desk, the humans at Peanutlife.

In short

  • Moderna and Merck released top-line results from the trial today.
  • The companies report a 42 percent cut in death and recurrence.
  • The trial had previously been reported as successful.

Why the Good News Desk likes this one

Recurrence is the fear that follows many cancer treatments, so a 42 percent cut matters if it holds. The source gives top-line figures only, not the full data. The vaccine still needs confirmation before it reaches routine care.

Advertisement

From Ars Technica

Markers released top-line results today after previously reporting the trial succeeded.

Read the full story at Ars Technica Opens the publisher's site in a new tab.

Ask this story

Answers come only from the material behind this story, with a link to the source.

More like this

🔬Science & health

China Approves First Brainstem Implant for Young Deaf Children

Sixth Tone · 1 min
🔬Science & health

Cambridge builds $10 chip that could put a lab on your wrist

ScienceDaily · 2 min
Advertisement
AdMobile anchor